These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 11994035)

  • 41. Pertussis: Where did we go wrong and what can we do about it?
    Locht C
    J Infect; 2016 Jul; 72 Suppl():S34-40. PubMed ID: 27161992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acellular vaccines for preventing whooping cough in children.
    Zhang L; Prietsch SO; Axelsson I; Halperin SA
    Cochrane Database Syst Rev; 2011 Jan; (1):CD001478. PubMed ID: 21249646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine.
    Rendi-Wagner P; Kundi M; Mikolasek A; Vécsei A; Frühwirth M; Kollaritsch H
    Vaccine; 2006 Aug; 24(33-34):5960-5. PubMed ID: 16757063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acellular pertussis vaccine for adolescents.
    de Carvalho AP; Pereira EM
    J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S15-24. PubMed ID: 16786100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
    Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Monitoring of a whooping cough epidemic 1994/95 in Switzerland using the sentinel notification system. Sentinella Registry].
    Matter HC; Schmidt-Schläpfer G; Zimmermann H
    Schweiz Med Wochenschr; 1996 Aug; 126(34):1423-32. PubMed ID: 8848704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Whole-cell and acellular pertussis vaccines.
    Wintermeyer SM; Nahata MC; Kyllonen KS
    Ann Pharmacother; 1994; 28(7-8):925-39. PubMed ID: 7949515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is there a need for a new generation of vaccines against pertussis?
    Storsaeter J; Wolter J
    Expert Opin Emerg Drugs; 2006 May; 11(2):195-205. PubMed ID: 16634696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. National study of infants hospitalized with pertussis in the acellular vaccine era.
    Elliott E; McIntyre P; Ridley G; Morris A; Massie J; McEniery J; Knight G
    Pediatr Infect Dis J; 2004 Mar; 23(3):246-52. PubMed ID: 15014301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New pertussis vaccination approaches: en route to protect newborns?
    Locht C; Mielcarek N
    FEMS Immunol Med Microbiol; 2012 Nov; 66(2):121-33. PubMed ID: 22574832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
    Scott LJ
    BioDrugs; 2010 Dec; 24(6):387-406. PubMed ID: 21043546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A nested case-control study measuring pertussis vaccine effectiveness and duration of protection in Manitoba, Canada, 1992-2015: A Canadian Immunization Research Network Study.
    Wilkinson K; Righolt CH; Kwong JC; Schwartz KL; Russell ML; Crowcroft NS; Mahmud SM
    Vaccine; 2019 Nov; 37(48):7132-7137. PubMed ID: 31564453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
    Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
    Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pertussis in the Era of New Strains of Bordetella pertussis.
    Souder E; Long SS
    Infect Dis Clin North Am; 2015 Dec; 29(4):699-713. PubMed ID: 26337739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
    Gustafsson L; Hessel L; Storsaeter J; Olin P
    Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Global pertussis epidemiology and immunization strategies].
    Zhang WH
    Zhongguo Yi Miao He Mian Yi; 2009 Oct; 15(5):467-72. PubMed ID: 20084979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pertussis in infants and the resurgence of a vaccine preventable disease: what to do? Commentary.
    Fedele G; Stefanelli P
    Ann Ist Super Sanita; 2017; 53(2):100-103. PubMed ID: 28617254
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany.
    Tormans G; Van Doorslaer E; van Damme P; Clara R; Schmitt HJ
    Eur J Pediatr; 1998 May; 157(5):395-401. PubMed ID: 9625337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.